🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

ABVC BioPharma, Inc. ABVC PHARMA

Healthcare · Biotechnology · United States
https://www.abvcpharma.com
Company Profile ↓
$1.06
-64.31% 1Y
Mkt Cap$28.25M
P/E-3.66
P/B2.40
52W High$3.30
52W Low$0.71
Book Value$0.40
EPS (TTM)$-0.29

Company Overview

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.24.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:-64.31%
6 Months:-27.40%
3 Months:-20.90%
1 Month:+3.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 14% of range
$0.71 $3.30
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)57.12 · Neutral
Price Performance
1M+3.92%
3M-20.90%
6M-27.40%
1Y-64.31%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Trading 67.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.66
Industry PE
24.83
Forward P/E
-2.41
PEG Ratio
-
Book Value
$0.40
Price to Book
2.40
P/S
-
EV/EBITDA
-4.97
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-48.00%
ROE
-69.86%
ROA
-22.85%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.06
EPS (TTM)
$-0.29

Balance Sheet & Liquidity

Debt/Equity
0.24
Quick Ratio
0.02
Current Ratio
0.07
Debt
$2.89M
Total Assets
$19.73M
Current Assets
$648.85K
Working Capital
$-3.66M

Ownership

Promoter Holding
18.11%
Chg in Prom Hold
-0.45%
FII / Inst Holding
4.09%
Chg in FII Hold
0.80%

Financial Snapshot

Enterprise Value
$28.25M
Total Revenue (TTM)
$0
EBITDA
$-6.49M
Free Cash Flow
$1.56M
Operating Cash Flow
$-2.69M
Shares Outstanding
26.65M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABVC ABVC BioPharma, Inc. PHARMA 1.06 -3.66 $28.25M 0.00% -48.00% -69.86% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2013Mar 2014Jun 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 00002.26K0----70.00K-90.00K--3.23K747212.24K191.78K197.73K78.79K226.51K115.55K263.15K31.44K99.00K25.66K312.86K42.27K128.27K6.11K15.88K1.21K117.14K389.28K000-795.95K0
Cost of Revenue -----------------------------------00000
Gross Profit -00-1.96K0---32-70.00K-90.00K--910210210.74K178.43K194.94K74.83K222.28K106.93K261.90K30.80K98.61K23.76K304.49K31.53K68.04K-66.87K-13.73K928116.95K388.98K000-795.95K0
Operating Expenses -----------------------------------693.00K2.29M1.96M2.20M1.57M
Operating Income -10-30-30-1.03K1.12K-1.50K-315.60K-3.50M-6.61M-289.10K-140.39K-236.84K-189.48K-3.36M-674.20K-524.43K-396.29K-730.57K-488.81K-1.12M-1.17M-1.19M-1.29M-1.25M-2.04M-1.97M-6.22M-2.05M-3.72M-1.91M-2.19M-2.15M-2.84M-860.11K-302.32K-693.00K-2.29M-1.96M-2.99M-1.57M
EBITDA ------------------------------------607.27K-2.10M-1.96M-3.57M-1.55M
Interest Expense -----------------------------------222.97K129.41K30.96K32.55K49.38K
Pretax Income ------------------------------------944.19K-2.31M-2.08M-3.81M-1.69M
Tax Provision -----------------------------------023.63K52700
Net Income -10-30-30-1.03K1.12K-1.50K-315.60K-3.50M-6.61M-293.24K-140.34K-256.67K-217.88K-3.39M-713.62K-736.04K-687.30K-873.32K-614.45K-1.33M-1.31M-2.18M-2.13M-1.20M-1.97M-1.81M-6.00M-1.86M-3.70M-1.82M-2.26M-3.32M-2.83M-942.34K-394.77K-842.08K-2.26M-2.04M-3.56M-1.56M
Diluted EPS ------0.00-0.02--0.000.000.00-0.02-0.05-0.050.00-0.05-0.03--0.06-0.09-0.09-0.05-0.08-0.07-0.20-0.59-1.14-0.55-0.68-0.82-0.29-0.08-0.03-0.06-0.13-0.09--0.06
R&D Expense -------3.50M6.50M-25.20K25.15K17.50K3.08M248.11K56.70K54.51K421.96K87.77K269.24K92.79K139.08K134.50K121.31K358.88K263.42K359.40K532.78K305.48K334.98K514.44K141.31K69.07K40.40K37.83K28.86K33.28K29.89K-33.10K

Profit & Loss (Annual)

Figures in USD.

Metric Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Dec 2015Sep 2016Sep 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 3.19K5.71K7.79K03.36K50.00M---6.96K701.72K483.05K-969.78K152.43K509.59K0
Cost of Revenue -------------286.42K302.04K7630
Gross Profit ---02.84K--32---178.32K681.58K464.33K-683.37K-149.61K508.83K0
Operating Expenses -------------15.80M6.62M5.21M7.15M
Operating Income -1.89M-1.14M-177.26K----11.00M-4.00M-4.14M-2.78M-3.46M-8.51M--15.11M-6.77M-4.71M-7.15M
EBITDA --------------15.20M-6.33M-4.34M-7.43M
Interest Expense -------------293.97K1.31M825.90K415.89K
Pretax Income --------------15.51M-8.02M-5.37M-8.35M
Tax Provision -------------797.78K256.01K-110.54K24.15K
Net Income -1.22M-1.07M-226.35K-70-32.28K--11.01M-4.07M-4.24M-6.06M-3.93M-10.59M--16.42M-7.79M-4.90M-7.91M
Diluted EPS -------0.06-0.02-0.02-0.02--0.50--5.20-1.80-0.42-0.39
R&D Expense ------10.00M3.15M3.17M988.72K1.05M549.66K1.00M2.69M1.06M179.27K121.08K

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Jul 2015Sep 2015Sep 2016Dec 2016Sep 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -369.40K302.31K231.97K65.39K-1.00M177.35K-2.75M2.64M5.94M6.93M11.61M-9.58M7.78M7.54M21.06M
Current Assets ---------------2.99M1.66M2.18M2.50M
Cash & Equivalents 2.81K71.78K13.39K6180-994.83K173.54K18.64K204.85K93.33K226.69K144.29K4.27M-85.27K60.16K248.38K681.48K
Inventory --------------25.98K0---
Receivables --------------280.69K98.33K1.53K0-
Total Liabilities ----34.03K-369.10K6.56M-4.15M4.40M11.28M7.05M8.94M-6.34M6.53M6.82M7.76M
Current Liabilities -1.83M1.95M2.11M34.03K-----4.40M10.99M6.81M4.84M-5.54M6.10M6.56M6.16M
Long Term Debt -------------------
Total Debt ---------------3.05M2.60M2.43M3.47M
Total Equity -2.99M-1.46M-1.64M-1.88M31.36K897.00K633.36K-6.38M-6.52M-1.39M-1.76M-5.66M-150.96K3.44M-3.10M1.55M1.23M11.11M
Shares Outstanding ---------------3.31M7.94M13.87M25.05M

Cash Flows (Annual)

Figures in USD.

Metric Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.59M-915.12K-37.77K1.17K3.36K-3.47M-1.60M-1.49M-900.53K-3.13M-4.56M--7.40M-4.19M-1.81M-2.99M
Investing Cash Flow -38.74K-19.55K000----156.37K-35.30K-225.43K--1.72M-360.19K0-1.21M
Financing Cash Flow 1.70M876.27K25.00K002.65M1.63M1.56M896.86K3.09M9.57M-4.01M3.87M1.98M4.64M
Capital Expenditure -29.82K-350-0---------17.50K-119.69K-21.20K--
Free Cash Flow -1.62M-915.47K-37.77K----------7.52M-4.21M-1.81M-2.99M
Net Change in Cash -------------5.11M-677.07K171.62K442.91K

Ratios (Annual)

Figures in %.

Metric Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Dec 2015Sep 2016Sep 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----84.5%-----2,563.6%97.1%96.1%-70.5%-98.1%99.9%-
Operating Margin % -59,180.7%-20,004.3%-2,276.3%-------40,031.1%-492.9%-1,760.9%--1,558.5%-4,439.2%-923.3%-
Net Margin % -38,202.2%-18,718.6%-2,906.8%--960.7%-----87,184.2%-560.5%-2,193.1%--1,693.5%-5,109.3%-962.1%-
ROE % 83.3%65.1%12.0%-0.2%-5.1%-172.6%292.3%241.5%107.2%2,605.4%-308.1%--530.0%-501.1%-399.9%-71.2%
ROCE % 129.0%69.5%9.4%-----235.6%55.2%-3,044.2%-125.8%--374.5%-402.2%-478.9%-48.0%

Shareholding Pattern

Insiders
18.11%
Institutions
4.09%
Public Float
4.99%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 1.41% 374.50K $434.42K
2 Geode Capital Management, LLC 0.86% 228.04K $264.53K
3 Vanguard Fiduciary Trust Co 0.37% 97.36K $112.94K
4 State Street Corporation 0.27% 72.80K $84.45K
5 Citadel Advisors Llc 0.27% 72.09K $83.62K
6 Blackrock Inc. 0.21% 56.44K $65.47K
7 Northern Trust Corporation 0.18% 48.64K $56.42K
8 Xtx Topco Ltd 0.18% 48.28K $56.00K
9 PanAgora Asset Management, Inc. 0.14% 36.68K $42.55K
10 UBS Group AG 0.13% 34.12K $39.58K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABVC

Yahoo Finance ue, 23 Jun 2026

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

SILICON VALLEY, CA - June 23, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingredient platforms, tod…

Yahoo Finance ue, 03 Mar 2026

ABVC BioPharma Reports 2025 Form 10-K

Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model SILICON VALLEY, CA - March 3, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) today announced the filing of its Annual Report on Form…

Yahoo Finance ue, 24 Feb 2026

ABVC BioPharma Provides Corporate and Structural Update

SILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingredient platforms,…

Yahoo Finance ue, 02 Dec 2025

ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States

SILICON VALLEY, CA - December 2, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today addressed recent public discussions surrounding attention-deficit/hyperactivity disorder (ADHD) treatment in the Unit…

Yahoo Finance Wed, 26 Nov 2025

ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030

SILICON VALLEY, CA - November 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today announced that its wholly owned subsidiary, BioKey (Cayman), Inc. ("BioKey"), has strengthened its operational platf…

Yahoo Finance Fri, 21 Nov 2025

ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received

SILICON VALLEY, CA - November 21, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) announced today that ForSeeCon Eye Corporation ("ForSeeCon") has made an additional US$250,000 payment under the existing …

ABVC — Frequently Asked Questions

What is the current share price of ABVC BioPharma, Inc. (ABVC)?

As of 2026-09-19 21:16 PDT, ABVC BioPharma, Inc. (ABVC) trades at $1.06 on NasdaqCM. Its 52-week range is $0.71 to $3.30.

What is the market capitalisation of ABVC?

ABVC BioPharma, Inc. (ABVC) has a market capitalisation of $28.25M on NasdaqCM.

What is the P/E ratio of ABVC?

ABVC trades at a trailing price-to-earnings (P/E) ratio of -3.66. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.40.

What is the return on equity (ROE) of ABVC?

ABVC has a return on equity (ROE) of -69.86%. Its return on capital employed (ROCE) is -48.00%.

Is ABVC a good stock to buy?

This page provides a data-driven analysis of ABVC BioPharma, Inc. (ABVC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space